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ABSTRACT
Infection of grouper sleepy disease iridovirus (GSDIV) which is a member of Megalocytivirus causes mass
mortalities in marine fish in Indonesia. This study was conducted to know the effectiveness of recombinant
subunit vaccine of GSDIV with an addition of adjuvants against GSDIV infection. Inactive bacteria Eschericia
coli containing recombinant MCP-GSDIV protein was added with montanide ISA adjuvant at a ratio of 3:7.
The vaccine was administered to humpback grouper, Cromileptes altivelis by intramuscular and intraperitoneal
injection at a dose of 0.1 mL/fish. Test of the vaccine in humpback grouper was performed in four replicates
(four trials). Results of the vaccination showed that the recombinant protein vaccine added with the
adjuvant increased immunity of humpback grouper, indicated by higher relative percent survival (RPS=
77.78%) compared to negative control (PBS) and 50% higher compared to protein control (pET Sumo CAT)
at two weeks post vaccination. The RPS values of the recombinant protein vaccine were still higher (53.57%-
72.73%) than those of the control vaccine and 25%-53.33% of the protein control in the 4th week post
vaccination. GSDIV detection by PCR showed that MCP-GSDIV-DNA and pET Sumo CAT-DNA were not
detected in the vaccinated fish after one, two, three, and four weeks post vaccination. The fish died in both
of vaccinated and control groups after experimental challenge with GSDIV were found to be infected with
GSDIV. It can be stated that recombinant subunit vaccine of GSDIV with the addition of montanide ISA
adjuvant could be used to prevent and diminish mortalities of grouper against GSDIV infection.
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INTRODUCTION
Economic losses caused by iridovirus infection in
aquaculture were considerably high. The virus causes
mass mortality in both marine and fresh water fish.
In Indonesia, iridovirus was known to infect marine
fish such as orange-spotted grouper (Epinephelus
coioides) (Koesharyani et al., 2001), tiger grouper
(E. fuscoguttatus), camouflage grouper
(E. polyphekadion), coral-trout grouper (Plectropomus
leopardus) , and cobia (Rachycentron canadum )
(Mahardika et al., 2009). Fresh water fish, for instance
Dwarf gurami (Colisa lalia ) , African lampeye
(Aplocheilichthys normani) (Sudthongkong et al., 2002a),
gourami (Osphronemus goramy), and Osteochillus hasselti
(Koesharyani, unpublished data) had also been reported
to be infected with iridovirus.
Grouper sleepy disease iridovirus (GSDIV) is a
member of the genus Megalocytivirus, belongs to the
family Iridoviridae. GSDIV has been known to attack
blood-forming organs (hematopoietic cells)
including spleen and kidney. Infection of GSDIV causes
anemia symptoms such as body weakened and lying
on the bottom of the tank with a pale or black body
color (Mahardika et al., 2009). In addition, according
to histopathological study, GSDIV infection can be
detected by the presence of inclusion body bearing
cells (IBCs) and necrotic cells that are observed as
enlarged cells under a light microscope.
Morphologycally, iridovirus is hexagonal in shape, 150-
200 nm in diameter, and multiplies in the cytoplasm
of the infected cells (Miyazaki, 2007).
In the previous study, an attempt had been made
to develop recombinant subunit vaccine using bacte-
ria E. coli which containing of the Major Capsid Pro-
tein (MCP) gene of Indonesian isolate of fish
Megalocytivirus. The recombinant subunit vaccine of
GSDIV could increase immunity of humpback
grouper after experimental challenge with GSDIV.
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However, the effectiveness of the vaccine was rela-
tively short (only two weeks post vaccination)
(Mahardika & Mastuti, 2015). Therefore, it is required
to add an adjuvant which is known to enhance im-
mune responses and improve vaccine potency. Adju-
vants assist with early immunity onset, long effector
response (antibody titres; T cell activity) and dimin-
ishing requirement of boosters. The main function
of adjuvants is the antigen presentation process, dis-
tinguishing them in Signal-1 (actual antigenic presen-
tation) and Signal-2 (secondary signals) facilitators;
both involved in the activation of lymphocytes T and
B (Tafalla et al., 2013 in Roldan, 2014). Adjuvants can
be classified by physical or chemical characteristics,
but also by the immunomodulating activity they de-
velop. Signal-1 adjuvants include oil emulsions and
micro/nanoparticles. Oil emulsion adjuvants have the
advantage of achieving a slow release that increases
immunogenicity; the emulsion is a dispersion of a
non-miscible liquid (dispersed phase= antigenic me-
dia) in a second liquid (continuous phase= oil). The
first oil based adjuvant was Freund´s adjuvant based
on heat killed Mycobacteria plus mineral oil and sur-
factant. Later came oil adjuvants that aimed to in-
crease efficacy and delivery, such as MontanideTM
(SEPPIC, France). These are mineral oil adjuvants,
optimized to improve efficacy, stability and reduce
side effects; they are based in mineral oil, non-
mineral oil, and mixtures, with mannitol oleate as
surfactant (Roldan, 2014). This study was conducted
as an effort to increase immunity of grouper against
GSDIV infection, and to enhance protection period
of the subunit vaccine of GSDIV through the addition
of MontanideTM ISA 763 A VG.
MATERIALS AND METHODS
Virus Stock
The fish Megalocytivirus used in the present study
was isolated from the naturally infected humpback
grouper (Cromileptes altivelis). The virus was obtained
from the spleen and kidney of the infected fish. The
spleen and kidney was homogenized in 9 x volume of
EMEM-2 and was centrifuged at 3,000 rpm for 15
minutes. Then, the supernatant was filtered at 0.45
µm2. The filtrate was then maintained at -80°C, and
used for DNA template, test vaccine, and virus propa-
gation in healthy fish.
Propagation of Bacteria as A Carrier of
Recombinant MCP-GSDIV Protein
The bacteria cell (E. schericia coli strain BL-21) as a
carrier of recombinant MCP-GSDIV protein vaccine
was confirmed by PCR and protein sequencing
(Mahardika & Mastuti, 2015). The bacteria cell were
cultured at mass scale in luria bertani (LB) broth me-
dia containing 50 µg/mL kanamycin at 37°C in rotary
shaker with speed of 225 rpm/minute for 24 h. Den-
sity of the harvested bacteria cell was measured by
plated into LB agar.
Expression of Protein Using IPTG
Cultured E. coli strain BL-21 was then induced us-
ing 0.1 mM IPTG (Isopropyl-β-D-Thiogalac-
topyranoside) and incubated in 37°C in rotary shaker
with speed of 225 rpm/minute for eight hour. A 50
mL of E. coli strain BL-21 culture that had been in-
duced using IPTG was centrifuged at 6,000 rpm for
ten minutes. After that, the pellet was lysed enzy-
matically using lysozyme, and mechanically by not only
freezing and thawing method, but also sonication to
obtain the protein. Lysing enzymatically was per-
formed by incubating 100 µL of the pellet with 150
µL lysozyme 200 mM at 37°C for five minutes. The
cells were then lysed by 30 cycles of freezing and
thawing (freezing at -80°C and thawing at 42°C), and
by sonication for 4 x 15 minutes. The lysed cells were
centrifuged at 15,000 rpm (maximum speed) for one
minute. A 10-15 µL of the pellet and 25 µL of the
supernatant were used for vertical electrophoresis
using SDS-page according to the method in our pre-
vious study (Mahardika & Mastuti, 2015).
Preparation of The Subunit Vaccine
Subunit vaccine is a vaccine produced from spe-
cific protein subunits of a virus and thus having less
risk of adverse reactions than whole virus vaccines.
In this study was used a subunit vaccine involves
putting an MCP gene from the GSDIV into bacteria
vector such E. coli to make a recombinant virus to
serve as the important component of a recombinant
vaccine (called a recombinant subunit vaccine).
A 5 mL of E. coli strain BL-21 culture that had been
induced with IPTG, density of 1.25 x 107 CFU/mL, and
had known to express protein by SDS-page was inac-
tivated by adding formalin (40%) until final concentra-
tion of 0.03%. The inactivation process was done
overnight at room temperature. The formalin was
then cleaned by centrifugation at 6,000 rpm for five
minutes to obtain pellet, and then the pellet was ly-
sed by sonication (4x 15 minutes). Following that,
the pellet was diluted in PBS in order to obtain den-
sity of 107 CFU/mL. At the 4th vaccination trial, the
volume of the vaccine was reduced at two times by
centrifugation; therefore, the concentration of the
bacteria was doubled.
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The Addition of Adjuvant
MontanideTM ISA 763 AVG (Seppic, France) is a
common adjuvant to be used for vaccination in aquac-
ulture. This product was selected based on the previ-
ous experience which was no mortality of fish after
one week administration of the adjuvant. E. coli BL-
21 was inactivated and then added with montanide
ISA 763 AVG (Seppic) at a volume ratio of 3:7 accord-
ing to the manual. Compound of the vaccine and the
adjuvant was emulsified or homogenized using a sy-
ringe without rubber (Discofix-3, Braun-Jermany) in a
clean bench. The homogenized vaccine was then
stored at 4°C until use. As well as recombinant sub-
unit vaccine of GSDIV, the recombinant subunit of
pET Sumo CAT as protein control was also emulsi-
fied with montanide ISA 763 AVG with same volume
ratio.
Test of The Recombinant Subunit Vaccine of
GSDIV in Humpback Grouper
Test of the subunit GSDIV vaccine was performed
in a total of 292 juvenile humpback grouper. The ju-
venile were 6-8 cm in size, and had been determined
negative to VNN and GSDIV by PCR analysis. The ju-
venile were divided into three groups for experiment
vaccination test. In group-I (vaccinated group), a to-
tal of 105 fish were administered with the emulsified
of recombinant subunit vaccine of GSDIV and (Ia) or
without (Ib) montanide ISA 763 AVG. In group-II (pro-
tein control group), a total of 84 fish were injected
with emulsified of recombinant subunit of pET Sumo
CAT and montanide ISA 763 AVG. In group-III (nega-
tive control), a total of 103 fish were injected with
phosphate buffer saline (PBS). Vaccination tests were
administrated by either intramuscular or
intraperitonial injection at a dose of 0.1 mL/fish. The
tests were done at a laboratory scale. The experi-
ment was carried out in four trials. In the 1st trial, the
fish were divided into three groups (group-Ia, II, and
III) which each group containing 25 fish, while in the
2nd trial, it was divided into four groups (group-Ia, Ib,
II, and III) which each group containing 10 fish. The
2nd trial was performed to know the effects of the
vaccination with and without addition of montanide
ISA 763 AVG. In the 3rd and the 4th trials, the test fish
were divided into three groups (group-I, II, and III)
which each group containing 30 fish. All fish for each
treatment were stocked into a happa with a size of
1 m x 1 m x 0.75 m and divided into four holes which
were floated in a 1,000 m3 tank. The vaccine was ad-
ministered once time according to the manual of
adjuvant Seppic manufacture’s distributor. Experimen-
tal challenge test with GSDIV virus was performed
after 14 and/or 30 days post vaccination by intramus-
cular injection (IM) at a dose of 0.1 mL/fish for the 1st
and 2nd trials, and by intraperitoneal injection (IP) at a
dose of 0.1 mL/fish for the 3rd and 4th trials. Particu-
larly for the 4th trial, the experiment was done in trip-
licates. Mortalities were recorded daily for 15 days
after the challenge test. Dead fish were autopsied to
determine the cause of death and to detect the pres-
ence of virus.
Effectiveness of the vaccine was determined by
relative percent survival (RPS) value after the experi-
mental challenge with GSDIV virus with lethal dose
of 80%. Data resulted from the challenge test were
presented in percent of mortality and RPS was calcu-
lated using the following formula:
In the 4th trial, data are expressed as mean ± SD.
A statistical analysis was performed using one-way
ANOVA for the RPS value. P<0.05 was taken to indi-
cate statistical significance.
Detection of GSDIV Virus by PCR Analysis
Detection of GSDIV virus by conventional PCR
analysis was done for sample of blood, spleen, and
liver after 1, 2, 3, and 4 weeks post vaccination, five
fish each. The PCR detection was also performed for
fish that were died after challenge test. The samples
were extracted using ISOGEN according to the
manual. PCR amplification was done using GoTaq®
PCR Core System I kit (Promega M7660) and the
primer used were MCP and pET Sumo (CAT) with a
molecular weight target of 1,362 bp and 1,313 bp.
Temperature of amplification was following the pre-
vious method (Mahardika & Mastuti, 2015). Results
of the amplification were analyzed by electrophore-
sis at a voltage of 100 V and 1.5% of gel agarose using
TAE buffer (2 Na EDTA 2 Na, Triss and Aquades) for
20-25 minutes. Staining was done using 0.5 mg/mL
ethidium bromide in TAE buffer. After the electro-
phoresis, the gel was read using ultraviolet
transiluminator.
Histopathological Observation
Histopathological observation was conducted to
the test fish with clinical sign (moribund). The fish
observed were 2-3 of the test fish at the last sam-
pling for each treatment, and five fish at 1, 2, 3, and
4 weeks post vaccination each. Condition of the in-
ternal organs of the fish was observed after dissec-
tion. Then, the internal organs (spleen, liver, kidney,
heart, stomach, and intestine) were fixed in 10% of
 
100 x 
control of mortality %
 treatmentof mortality %1
RPS


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phosphate buffer formalin. Particularly for gills, fixa-
tion was followed by decalcification using 5% formic
acid in 10% phosphate buffer formalin for 1-2 days
and was neutralized using 5% Na
2
SO
4
 in aquades. The
samples were processed using a method by Mahardika
et al. (2009). All samples were then embedded in
paraffin wax and were cut at a thick of 3–5 µm. Stain-
ing was done using haematoxylin-eosin (H&E).
RESULTS AND DISCUSSIONS
Expression of Protein
Recombinant plasmid was successfully expressed
the MCP-GSDIV protein in bacteria cells of E. coli strain
BL-21 induced by IPTG. The targeted MCP gene could
be expressed at a concentration of 0.1 mM IPTG.
Results of electrophoresis using SDS-page gel showed
molecular weight of the MCP recombinant at 60 kDa
(Figure 1).
Cloning of MCP gene from the virus isolate of
GSDIV derived from humpback grouper had been
successfully performed at Institute for Mariculture Re-
search and Development (IMRAD) at Gondol, in 2012
(Mahardika & Mastuti, 2015). The MCP gene had been
expressed completely and resulted in peptides with a
number of amino acid 453. The sequence of the amino
acids found in the present study was similar to the
MCP of Red Sea Bream Iridovirus (MCP-RSIV:
gi|29467056|BAC66968.1), and was agreed with the
sequence of MCP Megalocytivirus gene isolated from
South China Sea and South East Asian countries, which
consists of 1,362 and 1,372 base pairs and encode
454 amino acids (Sudthongkong et al., 2002b). The
MCP-RSIV had been reported to be used as recombi-
nant protein vaccine to prevent RSIV virus infection
(Shimmoto et al., 2010). The sequence of MCP-GSDIV
isolated locally from Indonesia was similar to the
sequence of MCP-RSIV which belongs to genus
Megalocytivirus. Therefore, recombinant protein of
GSDIV in this study could be used as recombinant
vaccine against Megalocytivirus infection in Indone-
sia. Potency of the recombinant MCP-GSDIV gene as
a vaccine will be discussed later.
In this study, the vaccine was constructed from
E. coli strain BL-21 as host cells inactivated in 0.03%
formalin and partially lysed by sonication. This pro-
cedure allows modulation of the non-specific immune
system in fish due to protein content in the bacteria
(Shimmoto et al., 2010). Proteomic analysis of pe-
ripheral blood mononuclear cells (PBMC) confirmed
that E. coli lipopolysaccharide induced differentially
over-expressed immune proteins such as complement
component C-3 and lysozyme C-2 precursor (Hang et
al., 2013).
Potency of The Protein Vaccine Against GSDIV
Infection
Administration of vaccine by intramuscular injec-
tion (IM) in the first trial (Table 1) showed that re-
combinant subunit vaccine of GSDIV with addition of
montanide ISA 763 AVG could increase the immunity
of humpback grouper against GSDIV infection after
14 and 30 days post vaccination. First, at 14 days
post vaccination, the increased in immunity of the
vaccinated fish (GSDIV + ISA) was indicated by higher
RPS (77.78%) compared to either of the fish adminis-
tered CAT (control protein) + ISA (55.56%) or the
non-vaccinated fish (injected with PBS). Second, at
30 days post vaccination, level of RPS of the fish
vaccinated with recombinant protein of GSDIV + ISA
was remained higher (57.14%) than that of the fish
administered by CAT + ISA (14.28%) and the non-
vaccinated fish.
In the 2nd vaccination (trial 2), intramuscular injec-
tion of the emulsified of montanide ISA 763 AVG and
recombinant subunit vaccine of GSDIV showed higher
RPS value (60% than those of the control fish group
(PBS) at 30 days post vaccination. The high RPS value
was also achieved by vaccination using recombinant
subunit vaccine of GSDIV without montanide ISA 763
AVG (16.67%) compared to the control fish group (PBS)
(Table 2).
Vaccination of emulsified of the montanide ISA
763 AVG with recombinant subunit vaccine of GSDIV
protein through intraperitoneal injection (the 3rd trial)
was also indicated higher RPS value (> 50%) than those
Figure 1. SDS-page gel shows target protein ex-
pression of the MCP gene resulting in 60
kDa (circle line). Line M: protein marker,
line-1: E. coli strain BL-21, lines-2 & 3: E.
coli strain BL-21 containing gen MCP-
GSDIV
   M     1       2        3 
60 kDa 
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of emulsified of the recombinant subunit of pET Sumo
CAT and negative control fish groups (Table 3).
In the last trial (the 4th trial), mortality of the fish
was relatively high. Therefore, average survival rate
was considerably low (< 20%) (Tabel 4). Neverthe-
less, administration of inactive bacteria containing
recombinant MCP-GSDIV protein at high concentra-
tion of the E. coli (1012 CFU/mL) and the addition of
the adjuvant, resulted in higher survival rate (33.33
± 3.33a) than those of the fish injected with protein
control CAT (P<0.05). However, survival rate of the
fish vaccinated with emulsified of the montanide ISA
763 AVG with recombinant subunit of GSDIV was not
significantly different with the non-vaccinated fish
(P>0.05) (Table 4).
Recombinant MCP-GSDIV protein vaccine has the
potential to induce immune system of fish against
GSDIV infection. This potency was indicated by higher
RPS value obtained in the vaccinated fish group than
that of the unvaccinated fish group (Mahardika &
Mastuti, 2015). Similarly, RPS value of the fish vacci-
nated by recombinant MCP-GSDIV protein vaccine was
higher compared to the fish administered by inactive
E. coli containing recombinant pET Sumo CAT pro-
tein. Results of the MCP-GSDIV test vaccine at a labo-
ratory scale exhibited relatively good protection
effect at 14 days post vaccination (RPS = 55%),
although it decreasing at 20-21 days post vaccination
(RPS < 33%).
Protection period of the recombinant protein
MCP-GSDIV vaccine was relatively short (< 20 days).
Therefore, montanide ISA adjuvant was added into
the vaccine. Results of the vaccine trials showed an
increase in immunity, and longer period of protec-
Table 1. RPS values of the vaccinated fish by intramuscular injection (IM)
Number of fish Mortality (%) RPS (%) Number of fish Mortality (%) RPS (%)
MCP + ISA 10 20 77.78 15 40 57.14
CAT (protein control) + ISA 10 40 55.56 15 80 14.28
PBS (negative control) 10 90 15 93.33
Treatments
14 days post vaccination 30 days post vaccination
Table 2. RPS values of the fish vaccinated with and without adjuvant in the second trial
Mortality (%) RPS (%) Mortality (%) RPS (%)
MCP +ISA 10 20 60 MCP 10 30 16.67
PBS (negative control) 10 50 PBS (negative control) 10 40
Days post 
vaccination
30 days 30 days
Treatments
(vaccine + adjuvant)
Number
of fish
Days post 
vaccination
Treatments 
(vaccine without  adjuvant)
Number
of fish
Table 3. RPS values of the vaccinated fish by intraperitoneal injection (IP)
Mortality 
(%)
RPS  comparison to PBS
 (RPS comparison to CAT) (%)
Tank 1 (IP)
MCP + ISA 15 25 53.57 (53.13)
CAT (protein control) + ISA 15 53.33 0.95
PBS (negative control) 13 53.85
Tank 2 (IP)
MCP + ISA 15 20 72.73 (53.33)
CAT (protein control) + ISA 14 42.86 41.56
PBS (negative control ) 15 73.33
30 days post vaccination
Number 
of fish
Treatments
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tion was achieved. This achievement indicated by
higher RPS value of the vaccinated fish, not only at
14 days post vaccination (> 70%) and (23%-73%) but
also at 30 days post vaccination compared to the
unvaccinated fish. RPS value of the fish group vacci-
nated with adjuvant was also higher than those of
the fish vaccinated without adjuvant. Those results
showed that the addition of montanide ISA adjuvant
in the recombinant MCP-GSDIV protein vaccine could
increase the effectiveness of the vaccine in stimu-
lating immune system indicated by the increase in
RPS value until one month post vaccination. In an-
other study, the increase in specific immunity was
also achieved when the RSIV vaccine was used to al-
leviate RSIV infection, signified by the increase in
serum antibody and expression of MHC class 1 which
are produced in response to infection (Caipang et al.,
2006). An MHC class I protein is anchored into the
cell membrane and extends upright into the extra-
cellular area. At the top of MHC class-I is a small
groove, which binds a specific peptide from a pro-
tein that has been digested within the cell. Tc cells
have T cell receptors (TCRs) on their membranes that
can bind to an MHC class-I that is presenting a anti-
gen. These TCRs can determine whether this pep-
tide is representative of normal cell function or an
implication that the cell has been infected (Campbell,
2010).
Virus Detection by PCR
Vaccination using inactive E. coli containing recom-
binant MCP-GSDIV protein and pET Sumo CAT showed
that there were either no MCP-GSDIV-DNA or pET
Sumo CAT-DNA detected in the vaccinated fish at 1,
2, 3, and 4 weeks post vaccination (Figure 2). These
results revealed that MCP-GSDIV-DNA or pET Sumo
CAT-DNA was cleared and could not be detected in
blood or target organs of GSDIV virus. Other possi-
bility is that those DNA had interacted with the fish
antibody and produce specific antibody that would
memorize the DNA. Similar to the vaccinated fish,
the PCR results of the unvaccinated fish did not show
any band in the gel agarose. Then, after the challenge
test, the survivors of all treatments were also nega-
tive to GSDIV infection confirmed by PCR.
Contrastingly, the fish that were died after the
challenge test were positively infected with GSDIV,
indicated by the presence of a band in the gel agar-
ose. The results are shown in Figure 2.
Histopathologycal Observation
Generally, vaccination by intramuscular injection
showed no irritation in the injection site of the
vaccinated fish. However, several fish suffered ulcers
at the injection site. On the contrary, most of the
fish vaccinated through intraperitoneal injection (>
80%) in the fourth trial exhibited pustule accumula-
tion in the abdominal cavity at the injection site
(Figure 3), whereas the internal organs such as liver,
intestine, stomach, spleen, kidney, and the heart were
appeared normal. Any pathological changes in the in-
ternal organs were also not found in the survivors
after the challenge test. However, the fish that were
died after the challenge test showed dilatation in the
spleen, and several of the fish showed black color or
pale in its hearts.
Histopathologically, clumps of pus in the abdomi-
nal-cavity appeared as abscess in the mesenterium
tissues. The abscess was red in color by hemato-
xylin-eosin staining (Figure 4A), and rounded by fi-
brinogen wall. The central part of the fibrinogen wall
showed cavity due to the pus run out of the wall
when embedding process (Figure 4B). Whereas other
internal organs were seen normal (Figure 4D). Ab-
scess was not found in the fish injected with PBS
(Figure 4C).
The newly dead fish of all treatments after the
challenge test showed the formation of enlarged cells
in the spleen and head kidney tissues (Figure 4E).
Those cells spread evenly and some of the cells were
contained in melanomacrophage center (MMC). The
enlarged cells appear bluish and reddish with some
variations in size. While in the heart tissue, the red
blood cells were accumulated in the blood vessels
(hyperemi), and outside of the blood vessel along
Table 4. Average survival rate of the test fish after the experimental
challenge with GSDIV virus for 15 days observation (Mean ± SD)
Treatments (Vaccine + montanide ISA 763 AVG (by IP)) Survival rate
MCP+ISA 33.33 ± 3.33a
CAT+ISA 30.0 ± 5.77a
PBS 33.33 ± 14.52a
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haemotocyte tissue nearby the blood vessels
(haemorrarghie). In addition, several enlarged cells
were circulated in the blood vessels.
While in the survivors of the control fish were
exhibited groups of enlarged cells in the spleen and
head kidney tissues (Figure 4F). The enlarged cells
together with other cells including melamine and
hemosiderin, forming a group of cells defined as
MMC.
Based on histopathology observation, the mori-
bund and fish just died in both of vaccine and control
groups revealed necrotic and formation of enlanged
cells in the kidney and spleen resulting in
spleenomegally. Dead fish were caused by anemia due
to damage of haematopitic cells. On the other hand,
necrotic, and enlarged cells were not observed in
survival fish. Spleen tissue just contained
melanomacrophage center (MMC) which normaly seen
in the fish recovered from GSDIV-disease (Miyazaki,
2007). Fish in the trial 1 to 3 did not shown any
Figure 2. PCR results of the test fish at 1, 2, 3, and 4 weeks after ad-
ministration of recombinant MCP-GSDIV protein vaccine,
pETSumo CAT (protein control), and PBS (negative control or
unvaccinated group). P : DNA Marker 100 bp, +: positive con-
trol, -: negative control
  1     2     3    4     +     P     -     1     2     3     4    +      
1,360 bp 
1,313 bp 
pET Sumo CAT MCP-GSDIV 
injury or abcess at the injection site of vaccine. In
the previous study, formation of enlarged cells and
necrosis were not found in the hematopoietic tissue
of the vaccinated fish. However, MMC was detected.
Although the MMC was found, there was no virus
particles observed in either the MMC or in the he-
matopoietic cells under an electron microscope ob-
servation (Mahardika et al., 2008).
In the present study, the concentration of E. coli
was increased by decreasing the initial volume of the
bacteria up to 100 times. Therefore, it was detected
that the concentration of inactive E. coli reached up
to 1012 CFU/mL. The use of high concentration of the
bacteria with the addition of the adjuvant (in the 4th
trial) causing accumulation of the vaccine and the
adjuvant at the injection site in the abdominal cavity.
This accumulation causing pustules that observed until
the fourth week post vaccination. The emergence of
the pustules was probably caused by the vaccine which
was not absorbed completely into the organs or tis-
Figure 3. Pathological sign of the vaccinated fish in the 4th trial; A) fish
injected with recombinant MCP-GSDIV vaccine showed pustule
accumulation in the abdominal-cavity (circle line) at the injection
site; B) unvaccinated fish showed normal abdominal-cavity with-
out any pathological changed
 
A B 
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Figure 4. Histopatological sign of the test fish administered by recombinant pro-
tein vaccine added with adjuvant; A) fish administered by recombinant
pET Sumo CAT in the 4th trial showed some abcess in the abdominal-
cavity (circle line) (magnification of 40X), B) detail of the abcess in figure
A (arrow) the abdominal-cavity was surrounded by fibrinogen (f) with bac-
terial invasion (magnification of 400X), C) mesenterium tissue of the
control fish (PBS) was normal (nr) with peripheral blood vessels (magnifi-
cation of 200X), D) spleen tissue of the fish administered by recombinant
protein MCP-GSDIV vaccine was seen normal (nr) (magnification of 400X),
E) spleen of fish just died of control fish group after the experimental
challenge with GSDIV showed formation of enlarged cells (arrows) as well
as necrotic cells (arrow heads), F) spleen of the survivors of the control
fish group after the experimental challenge with GSDIV showed groups
of enlarged cells defined as melanomacrophage center (mmc) (magnifica-
tion of 400X)
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sues of the fish, and could affect the health of the
fish. Consequently, the survival rate of the vaccinated
fish was low and statistically not different with those
of the unvaccinated fish after the experimental chal-
lenge with GSDIV virus.
CONCLUSION
The recombinant subunit vaccine of GSDIV with
the addition of montanide ISA 763 AVG adjuvant could
be used to prevent and to decrease mortalities of
grouper against GSDIV infection. The humpback grou-
per have a longer protection that indicating by the
better Relative Percentage Survival (RPS) value.
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